Search results
Insider Selling: Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) CEO Sells 9,064 Shares of Stock
ETF DAILY NEWS· 2 days agoRegeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) CEO Leonard S. Schleifer sold 9,064 shares of the ...
Jacobi Capital Management LLC Boosts Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
ETF DAILY NEWS· 4 days agoJacobi Capital Management LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by ...
Westwood Holdings Group Inc. Has $11.22 Million Stock Position in Regeneron Pharmaceuticals, Inc....
ETF DAILY NEWS· 7 days agoWestwood Holdings Group Inc. lowered its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 1.4% ...
...Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN - Regeneron...
Benzinga· 20 hours agoNEW YORK, June 15, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Regeneron Pharmaceuticals, Inc
Investors in Regeneron Pharmaceuticals (NASDAQ:REGN) have seen stellar returns of 220% over the past...
Simply Wall St. via Yahoo Finance· 2 days agoBut on a lighter note, a good company can see its share price rise well over 100%. Long term ...
Regeneron (REGN), SNY Win FDA Nod for Kevzara Label Expansion
Zacks via Yahoo Finance· 5 days agoRegeneron Pharmaceuticals, Inc. REGN and partner Sanofi SNY announced that the FDA has approved a...
RBC lifts Regeneron stock PT to $1,229 on higher sales estimetes of Dupixent By Investing.com
Investing.com· 4 days agoOn Wednesday, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) saw an increase in its price target to...
Analyst Report: Regeneron Pharmaceuticals, Inc.
Morningstar Research via Yahoo Finance· 1 day agoRegeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products ...
REGN, CI, BSX: Which “Strong Buy” Healthcare Stock Is the Best Bet?
TipRanks via Yahoo Finance· 3 days agoFor value investors looking to take a “break” from the euphoric technology stocks, many of which may...
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $1,229.00
ETF DAILY NEWS· 3 days agoRegeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its target price upped by Royal Bank of Canada from $1,200.00 to $1,229.00 in a research report sent to investors ...